General MedicationsINTRAMUSCULARStandard
RYKINDO
RISPERIDONE
Standard Dose
37.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview RYKINDO is listed in Drugs@FDA under application 212849 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient RISPERIDONE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 37.5MG Sponsor SHANDONG LUYE Submission history Latest submission status date: 2026-01-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview RYKINDO is listed in Drugs@FDA under application 212849 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient RISPERIDONE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 37.5MG Sponsor SHANDONG LUYE Submission history Latest submission status date: 2026-01-16 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.